Summary

Medical Aesthetic Products Market Research Report Information by Product (Botulinum Toxin (Botox), Dermal Fillers), by Application (Hair Removal, Skin Resurfacing, Facial Rejuvenation, Liposuction, Facelifts, Skin Grafting, Wrinkle Reduction, Others), by Gender (Male, Female), by End User (Hospitals & Dermatological Clinics, Medical Spas, Beauty Clinics), by Region (North America, Europe, Asia-Pacific, Rest of the World) Market Forecast Till 2032

Market Overview
In 2023, the market size of medical aesthetic products was estimated to be USD 8,971.27 million. The Global Medical Aesthetic Products industry is anticipated to experience a compound annual growth rate (CAGR) of 10.8% from USD 9,702.34 Million in 2024 to USD 22,032.40 Million by 2032. This growth is expected to occur over the forecast period of 2024 to 2032.
The Medical Aesthetic Products Market is being driven by the growing popularity of minimally invasive cosmetic procedures and the increasing approval and launch of dermal fillers and botox.
The Medical Aesthetic Products Market is experiencing substantial growth as a result of the growing popularity of minimally invasive cosmetic procedures. Botox and dermal fillers have become increasingly popular among consumers who are seeking effective solutions to improve their appearance without the extended recovery commonly associated with surgical options. These procedures are appealing to a wide range of individuals, including younger individuals who are pursuing preventative treatments, due to their immediate results and minimal discomfort. Advancements in techniques and formulations, in conjunction with the convenience and safety profile of these minimally invasive options, have rendered them highly appealing. The demand for these cosmetic interventions is anticipated to increase as a result of the ongoing increase in awareness of the benefits through social media and influencer endorsements, which is expected to drive the overall expansion of the market.

Market segment insights
The Medical Aesthetic Products Market has been segmented into botulinum toxin (Botox) and dermal fillers based on product. Botulinum toxin (Botox) is further divided into Type A and Type B. Dermal fillers are further divided into hyaluronic acid, calcium hydroxylapatite, poly-l-lactic acid, polymethyl-methacrylate microspheres (PMMA), and polyalkylimide.
The Market has been segmented into the following categories based on application: hair removal, skin resurfacing, facial rejuvenation, liposuction, facelifts, skin grafting, wrinkle reduction, and others.
The Medical Aesthetic Products Market has been segmented into male and female segments based on gender.
The market has been segmented into three categories: hospitals and dermatological clinics, medical spas, and cosmetic clinics, based on the end user.

Regional Perspectives
The Medical Aesthetic Products Market has been segmented into North America, Europe, Asia-Pacific, and the Rest of the World based on region. The market share of North America was the highest in 2023 and is expected to reach USD 8,594.84 million by 2032. Nevertheless, Asia-Pacific is anticipated to experience the most significant compound annual growth rate (CAGR) of 12.46% during the forecast period. In 2023, the Europe Medical Aesthetic Products Market was valued at USD 2,545.23 million and is anticipated to expand at a compound annual growth rate (CAGR) of 11.62% over the forecast period. Germany, France, the United Kingdom, Italy, Spain, and the rest of Europe are the additional segments of Europe. In 2023, the Asia-Pacific Medical Aesthetic Products Market was valued at USD 1,631.78 million and is anticipated to expand at a compound annual growth rate (CAGR) of 12.46% over the forecast period. The Asia-Pacific region is further divided into the following subregions: China, India, Japan, South Korea, Australia, New Zealand, and the Rest of Asia-Pacific.

Major Players
Suneva Medical, Abbvie, Inc., Bioxis Pharmaceuticals, Merz Pharma, Galderma, Sinclair, Medytox, Teoxane, and Dr. Korman are the primary participants in the Medical Aesthetic Products Market.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
3 RESEARCH METHODOLOGY
3.1 OVERVIEW
3.2 DATA FLOW
3.2.1 DATA MINING PROCESS
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
3.4.1 SECONDARY RESEARCH DATA FLOW:
3.5 PRIMARY RESEARCH:
3.5.1 PRIMARY RESEARCH DATA FLOW:
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
3.6.1 REVENUE ANALYSIS APPROACH
3.7 DATA FORECASTING
3.7.1 DATA FORECASTING TYPE
3.8 DATA MODELING
3.8.1 MICROECONOMIC FACTOR ANALYSIS:
3.8.2 DATA MODELING:
3.9 TEAMS AND ANALYST CONTRIBUTION
4 MARKET DYNAMICS
4.1 INTRODUCTION
4.2 DRIVERS
4.2.1 INCREASING POPULARITY OF MINIMALLY INVASIVE COSMETIC PROCEDURES
4.2.2 RISING APPROVAL AND LAUNCH FOR DERMAL FILLERS AND BOTOX
4.3 RESTRAINTS
4.3.1 SIDE EFFECTS ASSOCIATED WITH DERMAL FILLERS AND BOTOX
4.3.2 FOOD AND DRUG ADMINISTRATION (FDA) WARNING LETTER ASSOCIATED WITH THE DERMAL FILLERS
4.3.3 FAKE AND COUNTERFEIT VERSION OF BOTOX FILLERS
4.4 OPPORTUNITY
4.4.1 GROWING GERIATRIC POPULATION
5 MARKET FACTOR ANALYSIS
5.1 PORTER'S FIVE FORCES MODEL
5.1.1 THREAT OF NEW ENTRANTS
5.1.2 BARGAINING POWER OF SUPPLIERS
5.1.3 THREAT OF SUBSTITUTES
5.1.4 BARGAINING POWER OF BUYERS
5.1.5 INTENSITY OF RIVALRY
5.2 IMPACT OF COVID-19 ON MEDICAL AESTHETIC PRODUCTS MARKET
5.3 CONSUMER PREFERENCE
5.4 REGULATORY LANDSCAPE
5.4.1 NORTH AMERICA
5.4.2 EUROPE
5.4.3 ASIA-PACIFIC
5.4.4 MIDDLE EAST & AFRICA
5.5 MARKET TRENDS IN THE MEDICAL AESTHETIC PRODUCTS MARKET
5.6 PRICING ANALYSIS
5.7 LIST OF TRADERS AND DISTRIBUTORS REGION/COUNTRY
5.8 LIST OF MANUFACTURERS
5.9 PROCEDURE ANALYSIS ON REGIONAL LEVEL (2019-2023)
6 MEDICAL AESTHETIC PRODUCTS MARKET, BY PRODUCT
6.1 OVERVIEW
6.2 BOTULINUM TOXIN (BOTOX)
6.2.1 TYPE A
6.2.2 TYPE B
6.3 DERMAL FILLERS
6.3.1 HYALURONIC ACID
6.3.2 CALCIUM HYDROXYLAPATITE
6.3.3 POLY-L-LACTIC ACID
6.3.4 POLYMETHYL-METHACRYLATE MICROSPHERES (PMMA)
6.3.5 POLYALKYLIMIDE
6.3.6 OTHERS
7 MEDICAL AESTHETIC PRODUCTS MARKET, BY APPLICATION
7.1 OVERVIEW
7.2 HAIR REMOVAL
7.3 SKIN RESURFACING
7.4 FACIAL REJUVENATION
7.5 LIPOSUCTION
7.6 FACELIFTS
7.7 SKIN GRAFTING
7.8 WRINKLE REDUCTION
7.9 OTHERS
8 MEDICAL AESTHETIC PRODUCTS MARKET, BY GENDER
8.1 OVERVIEW
8.2 MALE
8.3 FEMALE
9 MEDICAL AESTHETIC PRODUCTS MARKET, BY END USER
9.1 OVERVIEW
9.2 HOSPITALS & DERMATOLOGICAL CLINICS
9.3 MEDICAL SPAS
9.4 BEAUTY CLINICS
10 MEDICAL AESTHETIC PRODUCTS MARKET, BY REGION
10.1 OVERVIEW
10.2 NORTH AMERICA
10.2.1 US
10.2.2 CANADA
10.3 EUROPE
10.3.1 GERMANY
10.3.2 FRANCE
10.3.3 UK
10.3.4 ITALY
10.3.5 SPAIN
10.3.6 REST OF EUROPE
10.4 ASIA PACIFIC
10.4.1 CHINA
10.4.2 INDIA
10.4.3 JAPAN
10.4.4 SOUTH KOREA
10.4.5 AUSTRALIA
10.4.6 NEW ZEALAND
10.4.7 REST OF ASIA PACIFIC
10.5 REST OF THE WORLD
10.5.1 MIDDLE EAST
10.5.2 AFRICA
10.5.3 LATIN AMERICA
10.5.3.1 ARGENTINA
10.5.3.2 BRAZIL
10.5.3.3 COLOMBIA
10.5.3.4 REST OF LATIN AMERICA
11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 MARKET SHARE ANALYSIS, DERMAL FILLERS, 2023
11.3 MARKET SHARE ANALYSIS, BOTULINUM TOXIN (BOTOX), 2023
11.4 COMPETITOR DASHBOARD
11.5 PUBLIC PLAYERS STOCK SUMMARY
11.6 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
11.1 KEY DEVELOPMENTS & GROWTH STRATEGIES
11.1.1 PRODUCT LAUNCH
11.1.2 PRODUCT APPROVAL
11.1.3 AGREEMENT
11.1.4 EXPANSION
12 COMPANY PROFILES
12.1 REVANCE THERAPEUTICS
12.1.1 COMPANY OVERVIEW
12.1.2 FINANCIAL OVERVIEW
12.1.3 PRODUCTS OFFERED
12.1.4 KEY DEVELOPMENTS
12.1.5 SWOT ANALYSIS
12.1.6 KEY STRATEGIES
12.2 ABBVIE, INC.
12.2.1 COMPANY OVERVIEW
12.2.2 FINANCIAL OVERVIEW
12.2.3 PRODUCTS OFFERED
12.2.4 KEY DEVELOPMENTS
12.2.5 SWOT ANALYSIS
12.2.6 KEY STRATEGIES
12.3 SUNEVA MEDICAL
12.3.1 COMPANY OVERVIEW
12.3.2 FINANCIAL OVERVIEW
12.3.3 PRODUCTS OFFERED
12.3.4 KEY DEVELOPMENTS
12.3.5 SWOT ANALYSIS
12.3.6 KEY STRATEGIES
12.4 BIOXIS PHARMACEUTICALS
12.4.1 COMPANY OVERVIEW
12.4.2 FINANCIAL OVERVIEW
12.4.3 PRODUCTS OFFERED
12.4.4 KEY DEVELOPMENTS
12.4.5 KEY STRATEGIES
12.5 MERZ PHARMA
12.5.1 COMPANY OVERVIEW
12.5.2 FINANCIAL OVERVIEW
12.5.3 PRODUCTS OFFERED
12.5.4 KEY DEVELOPMENTS
12.5.5 KEY STRATEGIES
12.6 GALDERMA
12.6.1 COMPANY OVERVIEW
12.6.2 FINANCIAL OVERVIEW
12.6.3 PRODUCTS OFFERED
12.6.4 KEY DEVELOPMENTS
12.6.5 SWOT ANALYSIS
12.6.6 KEY STRATEGIES
12.7 SINCLAIR
12.7.1 COMPANY OVERVIEW
12.7.2 FINANCIAL OVERVIEW
12.7.3 PRODUCTS OFFERED
12.7.4 KEY DEVELOPMENTS
12.7.5 SWOT ANALYSIS
12.7.6 KEY STRATEGIES
12.8 MEDYTOX
12.8.1 COMPANY OVERVIEW
12.8.2 FINANCIAL OVERVIEW
12.8.3 PRODUCTS OFFERED
12.8.4 KEY DEVELOPMENTS
12.8.5 KEY STRATEGIES
12.9 TEOXANE
12.9.1 COMPANY OVERVIEW
12.9.2 FINANCIAL OVERVIEW
12.9.3 PRODUCTS OFFERED
12.9.4 KEY DEVELOPMENTS
12.9.5 KEY STRATEGIES
12.10 DR. KORMAN
12.10.1 COMPANY OVERVIEW
12.10.2 FINANCIAL OVERVIEW
12.10.3 PRODUCTS OFFERED
12.10.4 KEY DEVELOPMENTS
12.10.5 KEY STRATEGIES
13 DATA CITATIONS